Drug Information
Drug (ID: DG00039) and It's Reported Resistant Information
Name |
Sulfasalazine
|
||||
---|---|---|---|---|---|
Synonyms |
Sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine
Click to Show/Hide
|
||||
Indication |
In total 2 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
Rheumatoid arthritis [ICD-11: FA20]
[2]
|
||||
Target | ATP-binding cassette transporter G2 (ABCG2) | ABCG2_HUMAN | [1] | ||
Nuclear factor NF-kappa-B (NFKB) |
NFKB1_HUMAN
; NFKB2_HUMAN ; TF65_HUMAN ; RELB_HUMAN ; REL_HUMAN |
[1] | |||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C18H14N4O5S
|
||||
IsoSMILES |
C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
|
||||
InChI |
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)
|
||||
InChIKey |
NCEXYHBECQHGNR-UHFFFAOYSA-N
|
||||
PubChem CID | |||||
ChEBI ID | |||||
TTD Drug ID | |||||
VARIDT ID | |||||
INTEDE ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
IDUE: Irregularity in Drug Uptake and Drug Efflux
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-13: Digestive system diseases
Ulcerative colitis [ICD-11: DD71]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [1] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Disease | Ulcerative colitis [ICD-11: DD71.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | CaCo2 cells | Colon | Homo sapiens (Human) | CVCL_0025 |
IPS cells | Colon | Homo sapiens (Human) | N.A. | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
Ussing chamber system assay | |||
Mechanism Description | Digoxin and fexofenadine (each 5 uM) were selected as P-gp substrates, and sulfasalazine and rosuvastatin (each 5 uM) were selected as BCRP substrates to evaluate the efflux transport mediated by P-gp and BCRP. PSC833 (15 uM) and ko143 (15 uM) were used as typical inhibitors of P-gp and BCRP, respectively. Serosal-to-mucosal transport of all the tested P-gp and BCRP substrate drugs was significantly decreased or tended to decrease in the presence of P-gp/BCRP inhibitor cocktail. |
ICD-15: Musculoskeletal/connective-tissue diseases
Rheumatoid arthritis [ICD-11: FA20]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Rheumatoid arthritis [ICD-11: FA20.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Mechanism Description | MTX is a substrate for eight ABC transporters. In vitro studies demonstrated that RAFLS treated with MTX had higher ABCB1 expression levels than controls, with a positive correlation between ABCB1 expression levels and RA treatment duration. In addition to MTX, other DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, azathioprine), glucocorticoids (e.g. betamethasone, dexamethasone), and NSAIDs (e.g. celecoxib and indomethacin) are also substrates of ABC transporters. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.